Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals

• Published in: Vaccines (Basel) Vol. 10; no. 5; p. 817
• Main Authors: Lapa, Daniele, Grousova, Daria M, Matusali, Giulia, Meschi, Silvia, Colavita, Francesca, Bettini, Aurora, Gramigna, Giulia, Francalancia, Massimo, Garbuglia, Anna Rosa, Girardi, Enrico, Puro, Vincenzo, Antinori, Andrea, Kovyrshina, Anna V, Dolzhikova, Inna V, Shcheblyakov, Dmitry V, Tukhvatulin, Amir I, Zubkova, Olga V, Gushchin, Vladimir A, Logunov, Denis Y, Naroditsky, Boris S, Vaia, Francesco, Gintsburg, Alexander L
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 21.05.2022; MDPI
• Subjects: Antibodies; antibody response; Coronaviruses; Correlation analysis; COVID-19; COVID-19 vaccines; Immunization; Infections; Infectious diseases; Neutralization; Neutralizing; Omicron; Plasma; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Statistical analysis; vaccine; Vaccines; Viruses; Italy; SARS-CoV-2; vaccine; antibody response; Omicron; neutralization
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines10050817

The new Omicron variant of SARS-CoV-2, first identified in November 2021, is rapidly spreading all around the world. Omicron has become the dominant variant of SARS-CoV-2. There are many ongoing studies evaluating the effectiveness of existing vaccines. Studies on the neutralizing activity of vaccinated sera against the Omicron variant are currently being carried out in many laboratories. In this study, we have shown the neutralizing activity of sera against the SARS-CoV-2 Omicron variant compared to the reference Wuhan D614G variant in individuals vaccinated with two doses of Sputnik V up to 6 months after vaccination and in individuals who experienced SARS-CoV-2 infection either before or after vaccination. As a control to our study we also measured neutralizing antibody titers in individuals vaccinated with two doses of BNT162b2. The decrease in NtAb titers to the Omicron variant was 8.1-fold for the group of Sputnik V-vaccinated individuals. When the samples were stratified for the time period after vaccination, a 7.6-fold or 8.8-fold decrease in NtAb titers was noticed after up to 3 and 3-to-6 months after vaccination. We observed a 6.7- and 5-fold decrease in Sputnik V-vaccinated individuals experiencing asymptomatic or symptomatic infection, respectively. These results highlight the observation that the decrease in NtAb to the SARS-CoV-2 Omicron variant compared to the Wuhan variant occurs for different COVID-19 vaccines in use, with some showing no neutralization at all, confirming the necessity of a third booster vaccination.